Home » Newsletters » BioWorld Science

BioWorld Science

Oct. 30, 2007

View Archived Issues

Response rates not reduced by neutralizing antibodies to certolizumab pegol

Targacept to develop TC-5214 as augmentation therapy for depression

Novel dual adenosine A1 and A2A antagonist improves motor and cognitive function in PD models

Combination of morphine and new TRPV1 antagonist shows promise in bone cancer pain

Unigene successfully completes oral calcitonin study

Positive interim phase II results reported for the immunosuppressant LCP-Tacro

Genta files appeal to FDA over non-approval of Genasense for chronic lymphocytic leukemia

VIA Pharmaceuticals plans third phase II trial of VIA-2291 for acute coronary syndrome

Recent Novo Nordisk patent discloses novel antiobesity agents

FDA approves ANG-1005 for phase I/II clinical development

Recent Synta and Novartis patents divulge novel immunomodulatory agents

New therapeutic agents for cancer covered in recent patent literature

Isis to receive funding for IND-enabling studies on antisense drug for Huntington's disease

UCB initiates phase III clinical trials of brivaracetam for partial-onset epilepsy

Panacos announces preliminary results from the 300 mg cohort in a phase IIb trial of bevirimat

Clinical data on apoE-mimetic peptides in neurological injury

Positive phase III results for difluprednate for eye inflammation following ocular surgery

Positive phase III trial results announced for The Medicine Company's Cleviprex

Flamel Technologies announces positive results from clinical trial of IFN-alpha-XL

Chugai reports third quarter 2007 results

Preclinical antidepressant/anxiolytic effects of the neuronal nicotinic receptor antagonist TC-5214

SSR-103800, a GlyT1 inhibitor, alleviates hyperactivity in a transgenic mouse model of schizophrenia

Novel platinum-based compounds with improved in vivo activity on human xenograft models

Onconova presents new JAK2 inhibitor for the treatment of leukemia

Johnson & Johnson Pharmaceutical submits NDA for paliperidone palmitate

FDA approves Tasigna for CML patients with resistance/intolerance to current therapy

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 19, 2026.
Precision psychiatry beyond, or before, biomarkers
BioWorld
There is broad agreement that psychiatric diagnoses in their current form are not reflective of any underlying biology, and that this is one of the things...
ADPD 2026: Can we prevent dementia? Scientists quantify it
BioWorld
Neurodegenerative disease and cognitive decline cannot be explained by a single process. Beta-amyloid plaques, hyperphosphorylated tau, alpha-synuclein, activated...
Keros reports beneficial effects of RKER-065 in ALS model
BioWorld Science
Keros Therapeutics Inc. has presented data regarding their activin receptor ligand trap, RKER-065, for the inhibition of the activin/myostatin signaling axis.
First-in-class POLG activator restores mtDNA across mutations
BioWorld Science
Researchers from Pretzel Therapeutics Inc. presented preclinical data of PX-578, a first-in-class POLG activator aimed at restoring mtDNA replication and...